Company Overview
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Why Investors Should Care
Revenue has grown at a 43.0% CAGR over the past five years.
Trades at a P/E of 16.6, below the sector median of 25.2.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Trailing 12 Months Year-on-year growth — revenue -34.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 43.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 43.00% |
| 1 Year: | -33.98% |
Stock Price Performance
| 1 Year: | +343.79% |
| 6 Months: | +64.21% |
| 3 Months: | +93.56% |
| 1 Month: | +44.11% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)70.14 · Overbought
P/E of 16.62 is below the sector median of 25.17 — relatively cheaper than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 43.0% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | OMER Omeros Corporation R2KR3KPHARMA | 18.95 | 16.62 | $1.37B | 0.00% | -49.60% | 2.76% | 43.00% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 1.59M | 1.66M | 4.61M | 22.02M | 21.78M | 26.75M | 29.86M | 33.42M | 23.54M | 13.53M | 26.11M | 10.63M | 21.06M | 28.82M | 30.00M | - | - | - | - | - | - | - | - | - | 0 | - | - | 9.89M |
| Operating Income | -17.93M | -15.97M | -19.30M | -18.04M | -19.45M | -10.93M | -12.04M | -11.86M | -12.72M | -11.94M | -5.11M | -14.12M | -27.69M | -30.62M | -35.44M | -18.47M | -19.24M | -9.34M | -11.10M | -23.70M | -23.68M | -27.68M | -25.43M | -33.82M | -45.29M | -45.61M | -39.83M | -35.05M | -37.44M | -50.77M | -35.71M | -40.90M | -48.15M | -39.03M | -59.16M | -35.41M | -34.97M | -32.35M | -26.39M | -17.42M |
| Net Income | -18.67M | -16.68M | -19.92M | -19.83M | -20.54M | -12.61M | -13.96M | -19.63M | -15.09M | -14.36M | -7.48M | -16.55M | -30.05M | -33.70M | -39.47M | -23.53M | -24.34M | -14.45M | -16.46M | -29.23M | -29.03M | -33.29M | -38.46M | -37.27M | -35.09M | -28.59M | -22.70M | -33.01M | -30.85M | -17.46M | -33.70M | -37.29M | -37.75M | -37.18M | -56.04M | -32.23M | -33.46M | -25.42M | -30.92M | 56.06M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.61 | -0.66 | - | -0.57 | -0.46 | -0.36 | -0.53 | -0.49 | -0.28 | -0.54 | -0.59 | - | -0.63 | -0.97 | -0.56 | -0.58 | -0.43 | -0.47 | 0.62 |
| R&D Expense | 9.32M | 10.90M | 13.26M | - | 15.43M | 10.23M | 12.49M | - | 12.24M | 13.14M | 14.84M | - | 18.14M | 19.41M | 26.86M | - | 26.25M | 19.11M | 23.75M | - | 28.91M | 24.13M | 31.32M | - | 32.50M | 30.13M | 25.82M | 24.09M | 23.52M | 38.57M | 24.61M | 29.64M | 31.73M | 26.77M | 45.35M | 24.08M | 23.85M | 22.01M | 15.99M | 13.36M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.44M | 2.10M | 4.52M | 6.02M | 1.60M | 539.00K | 13.51M | 41.62M | 64.83M | 29.87M | 111.81M | 73.81M | - | - | - | - | - |
| Operating Income | -20.76M | -30.11M | -27.41M | -36.88M | -50.52M | -70.01M | -71.24M | -54.28M | -43.90M | -112.22M | -146.04M | -156.92M | -173.62M | -163.39M | -164.53M | -166.95M | -122.80M |
| Net Income | -21.09M | -29.25M | -28.55M | -38.44M | -39.80M | -73.67M | -75.10M | -66.75M | -53.48M | -126.76M | -84.49M | -138.06M | 194.24M | 47.42M | -117.81M | -156.81M | -3.35M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | -1.71 | -2.41 | 3.12 | 0.76 | -1.88 | -2.70 | -0.05 |
| R&D Expense | 16.93M | 23.46M | 23.72M | 31.92M | 36.30M | 47.95M | 48.38M | 50.70M | 55.60M | 89.86M | 106.32M | 107.61M | 118.78M | 112.72M | 114.87M | 119.52M | 81.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Oct 2016 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 45.70M | 26.98M | 26.57M | 16.54M | 10.83M | 48.99M | - | 67.28M | 116.33M | 95.94M | 136.97M | 181.04M | 419.27M | 590.97M | 378.27M | 277.08M | 325.63M |
| Total Equity | -91.17M | 43.15M | 20.47M | -5.55M | -6.53M | -18.38M | -42.65M | -26.23M | - | -37.45M | -2.81M | -100.16M | -109.02M | -120.75M | 23.78M | 85.68M | -24.98M | -182.61M | -121.23M |
| Cash & Equivalents | 12.73M | 820.00K | 3.28M | 4.00M | 1.52M | 1.38M | 354.00K | 1.36M | - | 2.22M | 3.39M | 5.86M | 3.08M | 10.50M | 100.81M | 11.01M | 7.11M | 3.40M | 9.66M |
| Long Term Debt | - | - | - | 13.55M | 20.10M | 14.90M | 26.12M | 49.77M | 70.00M | 79.51M | 84.12M | - | - | 236.29M | 313.46M | 315.29M | 213.16M | 164.90M | 87.90M |
| Current Liabilities | - | - | 15.37M | 18.98M | 8.36M | 11.87M | 18.32M | 16.25M | - | 16.07M | 26.31M | 37.36M | 55.46M | 36.74M | 51.79M | 136.38M | 53.32M | 79.53M | 78.06M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.03M | -14.50M | -25.67M | -34.55M | -29.70M | -58.04M | -65.21M | -51.50M | -36.23M | -103.74M | -60.07M | -100.09M | -109.72M | -86.48M | 74.73M | -148.80M | -116.09M |
| Investing Cash Flow | -52.40M | 19.92M | 16.91M | -907.00K | 7.91M | 6.16M | -20.61M | -16.34M | -37.60M | 25.15M | -3.40M | -67.03M | 193.71M | -127.56M | 27.45M | 82.22M | 164.52M |
| Financing Cash Flow | 59.52M | -2.96M | 9.49M | 32.97M | 21.65M | 50.86M | 86.83M | 68.70M | 75.00M | 81.05M | 60.70M | 174.53M | 6.32M | 124.25M | -106.08M | 62.88M | -42.17M |
| Capital Expenditure | -279.00K | -807.00K | -1.24M | -642.00K | -204.00K | -28.00K | -240.00K | -126.00K | -350.00K | -567.00K | -334.00K | -283.00K | -277.00K | -113.00K | -426.00K | -165.00K | -65.00K |
| Free Cash Flow | -19.31M | -15.31M | -26.91M | -35.19M | -29.90M | -58.07M | -65.45M | -51.63M | -36.58M | -104.30M | -60.41M | -100.37M | -110.00M | -86.60M | 74.30M | -148.97M | -116.16M |
| Share Buybacks | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 4.65M | 11.85M | 0 |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | -1,437.5% | -1,430.2% | -605.9% | -612.5% | -3,157.2% | -12,988.5% | -527.3% | -130.4% | -67.7% | -375.7% | -130.6% | -212.6% | - | - | - | - | - |
| Net Margin % | -1,460.5% | -1,389.6% | -631.0% | -638.4% | -2,487.2% | -13,668.5% | -555.9% | -160.4% | -82.5% | -424.4% | -75.6% | -187.0% | - | - | - | - | - |
| ROE % | -48.9% | -142.9% | 514.0% | 588.6% | 216.5% | 172.7% | 286.3% | 178.2% | 1,900.5% | 126.6% | 77.5% | 114.3% | 816.8% | 55.3% | 471.6% | 85.9% | 2.8% |
| ROCE % | - | -99.3% | -342.8% | -202.5% | -1,083.6% | 935.8% | -217.6% | -106.0% | -48.8% | -191.6% | -179.2% | -108.7% | -47.2% | -35.9% | -50.6% | -84.5% | -49.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 8.35% | 6.04M | $112.49M |
| 2 | Ingalls & Snyder LLC | 5.06% | 3.66M | $68.10M |
| 3 | UBS Group AG | 4.35% | 3.15M | $58.59M |
| 4 | Vanguard Capital Management LLC | 4.24% | 3.07M | $57.17M |
| 5 | State Street Corporation | 3.20% | 2.32M | $43.17M |
| 6 | Geode Capital Management, LLC | 2.64% | 1.91M | $35.63M |
| 7 | Stifel Financial Corporation | 2.54% | 1.84M | $34.19M |
| 8 | Vanguard Portfolio Management LLC | 1.33% | 962.83K | $17.92M |
| 9 | Corient Private Wealth LP | 1.11% | 801.41K | $14.91M |
| 10 | Invesco Ltd. | 1.04% | 751.77K | $13.99M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for OMER
OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxNU3R0X2ZzTGk4c1QtRkx0VHc1b3dNTEpSYkhzZ0FvSHNBNmowbC1INDljdzZ0bmgtSlRoT3lnSFZJOTBqWEdaSnVPa0M1TVlCajlLX3MwYVBmSFV5UXAzZWdrdzFYM2ZtT0pQUTNvZFowdXVyMUFieXpRS09fM1djQk9ZMllONFNwdW5FUl…
OMER Stock Gains Ground As Commercial Rollout Of Yartemlea Exceeds Expectations - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOdmxlOTFGdTRqV1ROSE1PWUNoeXhYY2E1Z2YxSGpDSFNPaTd0ZFl1Q2VLaTd6bDlabWYwVnQtMVR6eEZNLVBKd0JGLVdPNm5Ud3pGTU1neUlxTjk5RXJ4Tmg5YkY3dWIxUUx5VEJzUjlJWTlqRUoteW9PV042QUpjZGZtck1kYWh2YzB1Rn…
Omeros (OMER) Stock Looks Reasonable On Earnings But Stretched After A 431% Run - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNMmI4emFQQUdUd0FDeWJfMmtQWXItMXBsVnVsUkd6aTg0OUs1enZaRTdfakNyXzZLRU9SdHRBTzh3RS1oYS1qYUt4bk5EcC1GVmZ1VF9zdkpWbVBBXzF5a3dSRUM4a2xIODl2OWVnaGM4amJHTXBxV0RXVjJQTE4tcHdFODMzNDBYX3drMn…
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxQdEZfbHNrQ0dvVi1Jb0ZiY0VoWHdkNUtIWWFfalRrLXI0aTh1TkZZZTkwNTJHRE5MZWlMOGkwbGV1X3hwZmx1RWFLU2dtN3ZJQ3JYSGx5MnFWQU4waEx2U1pOY19MMUszZG9JeWNJQmwtVlV6R2FZM1JmXzd5OU8xVTM1dUozcXo5X3lGVG…
Insider Sale: VP of $OMER Sells 25,000 Shares - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMijAFBVV95cUxQLUhSYXRSWHdMRjVtamhzeHpLc1ZReUVtRHZSZ3FxS2hWTEZoWkNVLWhEQnRnOE4zdDFYVU5ZS3AtTklGOEFYZEg5Nkx2RkNzUkE4MjNYN2lIeHhUcWJOd0lpbER0bzVoWDZkUFcyWms4LUViR2stcU9tSlRVZEdSWkZIV3prbE1HdWNkSw…
Price-Driven Insight from (OMER) for Rule-Based Strategy - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizwFBVV95cUxOUVBEY0l4Z2htX2ZkejVGZ1FTNWVybC0tejRWNlJxbDY1VW9iVkM0QnJKc2lYWHR0ZERYWVZKWFlnaXROb0tyRjc3UXppLXhjMGU4WnIxMDEwNFdGRXRfTTFJUFNRNmJTRUJ3RDFVWnBzbEx2ZVhwZndXRTdkdmlnVDlxb2szR1FVM2RHLU…
OMER — Frequently Asked Questions
What is the current share price of Omeros Corporation (OMER)?
As of 2026-09-07 16:24 PDT, Omeros Corporation (OMER) trades at $18.95 on NasdaqGM. Its 52-week range is $4.03 to $19.32.
What is the market capitalisation of OMER?
Omeros Corporation (OMER) has a market capitalisation of $1.37B on NasdaqGM.
What is the P/E ratio of OMER?
OMER trades at a trailing price-to-earnings (P/E) ratio of 16.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -15.06.
What is the return on equity (ROE) of OMER?
OMER has a return on equity (ROE) of 2.76%. Its return on capital employed (ROCE) is -49.60%.
Is OMER a good stock to buy?
This page provides a data-driven analysis of Omeros Corporation (OMER), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.